|
Acute lymphocytic leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
36 (82%) of the patients with BCR-ABL1-like disease had deletions in genes involved in B-cell development, including IKZF1, TCF3, EBF1, PAX5, and VPREB1; only nine (36%) of 25 patients with B-other ALL had deletions in these genes (p=0.0002).
|
19138562 |
2009 |
|
Hematopoietic Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
VpreB gene expression in hematopoietic malignancies: a lineage- and stage-restricted marker for B-cell precursor leukemias.
|
1884024 |
1991 |
|
leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
VpreB RNA was also expressed in the neoplastic cells of one of three patients with acute undifferentiated leukemias.
|
1884024 |
1991 |
|
Precursor B-cell lymphoblastic leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
After approximately 5 months in culture on BM stromal cells plus IL-7, BLIN-3 sublines emerged expressing mu heavy chain and VpreB on the cell surfaces (ie, pre-B-cell receptor [BCR](+)).
|
11719380 |
2001 |
|
Blast Phase
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Chronic myeloid leukemia blast crises of the B-precursor-cell type expressed the VpreB gene while myeloid blast crises did not.
|
1884024 |
1991 |
|
Lupus Erythematosus, Systemic
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Coexpression of RAG and VpreB or CD154 mRNA could only be found in SLE B cells.
|
16126793 |
2006 |
|
Precursor B-cell lymphoblastic leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
During B-cell development, precursor B cells transiently express the pre-B-cell receptor composed of μ heavy chain complexed with VpreB and λ5 surrogate light chain polypeptides.
|
20823132 |
2010 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.310 |
Biomarker
|
disease |
CTD_human |
Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.
|
26214592 |
2015 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.
|
26214592 |
2015 |
|
L2 Acute Lymphoblastic Leukemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.
|
26214592 |
2015 |
|
Autoimmune Diseases
|
0.020 |
AlteredExpression
|
group |
BEFREE |
However, no autoantibody production was detectable in VpreB or λ5 transgenic mice and VpreB expression could not accelerate autoimmunity.
|
25523463 |
2015 |
|
Immune System Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
In humans, a copy number loss of 22q11.2, a region harboring the VPREB1 gene, has been suggested to be associated with several immunologic disorders, but there has been no study on the copy number variation (CNV) of the VPREB1 and its potential association with RA.
|
21144590 |
2011 |
|
Down Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In total, 50% of DS ALL patients had ≥1 deletion in the B-cell development genes: PAX5 (12%), VPREB1 (18%) and IKZF1 (35%).
|
22441210 |
2012 |
|
Complete Trisomy 21 Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In total, 50% of DS ALL patients had ≥1 deletion in the B-cell development genes: PAX5 (12%), VPREB1 (18%) and IKZF1 (35%).
|
22441210 |
2012 |
|
Autoimmune arthritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Instead, moderate VpreB expression partially protected mice from induced autoimmune arthritis.
|
25523463 |
2015 |
|
Impaired glucose tolerance
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
NAT2 A803 allele seems to play a role in worsening the destiny of obese children carrying it, predisposing them to elevated-1HPG and IGT and then to a possible future type 2 diabetes mellitus throughout an impairment of pancreatic β-cellular insulin secretion as suggested by oDI and IGI reduction.
|
27481583 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
NAT2 A803 allele seems to play a role in worsening the destiny of obese children carrying it, predisposing them to elevated-1HPG and IGT and then to a possible future type 2 diabetes mellitus throughout an impairment of pancreatic β-cellular insulin secretion as suggested by oDI and IGI reduction.
|
27481583 |
2017 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
None of the B-LBL cases showed abnormal, isolated VPREB1 deletion adjacent to IGL locus, which we identified in 25% of B-ALL.
|
27957801 |
2017 |
|
Acute lymphocytic leukemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
None of the B-LBL cases showed abnormal, isolated VPREB1 deletion adjacent to IGL locus, which we identified in 25% of B-ALL.
|
27957801 |
2017 |
|
Lymphoid leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
None of the B-LBL cases showed abnormal, isolated VPREB1 deletion adjacent to IGL locus, which we identified in 25% of B-ALL.
|
27957801 |
2017 |
|
Common acute lymphoblastic leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Northern blot analysis of RNAs from 63 leukemia samples showed that VpreB RNA was present in malignancies of precursor B cells, the expression being a feature of both common acute lymphoblastic leukemia (ALL) (CD10+) and null ALL (CD10-).
|
1884024 |
1991 |
|
Rheumatoid Arthritis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Studies of copy number variation in rheumatoid arthritis suggest that a reduced dosage of the VPREB1 gene is involved in disease pathogenesis.
|
24602812 |
2014 |
|
Diabetic Retinopathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
T2DM: Type 2 Diabetes Mellitus; HbA<sub>1C</sub>: Hemoglobin A<sub>1c</sub>; OHA: Oral Hypoglycemic Agents; STIT: Short-term Insulin Treatment; CSII: Continuous Subcutaneous Insulin Infusion; MDI: Multiple Daily Injections; PPG: Postprandial Plasma Glucose; FPG: Fasting Plasma Glucose; HOMA-b: Homeostasis Model Assessment of beta-cell function; TDD: Total Daily Insulin Dose; DI: Disposition Index; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; ROS: Reactive Oxygen Species; TNF: Tumor Necrosis Factor; GLP-1: Glucagon-like peptide-1; GIP: Glucose-dependent Insulinotropic Polypeptide; BMI: Body Mass Index; CV: Cardiovascular; DR: Diabetic Retinopathy; SU: Sulfonylurea; IGI: Insulinogenic Index.
|
30244600 |
2018 |
|
Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The use of Burkitt lymphoma and myelogenous leukemia cell lines with translocations in the 22q11 region led to a refinement in the location according to the following order: cen----BCRL2, VpreB, IgV lambda 1----BCRL4, IgV lambda----IgC lambda----BCR----BCRL3, lambda-like----tel.
|
1903358 |
1991 |
|
Adult Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The use of Burkitt lymphoma and myelogenous leukemia cell lines with translocations in the 22q11 region led to a refinement in the location according to the following order: cen----BCRL2, VpreB, IgV lambda 1----BCRL4, IgV lambda----IgC lambda----BCR----BCRL3, lambda-like----tel.
|
1903358 |
1991 |